Cleveland Diagnostics

Cleveland Diagnostics Cleveland Diagnostics offers novel, more accurate testing for early detection of cancer and risk of high-grade disease.

09/03/2026

In the first episode of On Call for Men’s Health: A PSA on PSA, urologist Dr. Michael Lutz sits down with Dr. John Oliffe to talk about the mental health side of prostate cancer, including the fear and stress that follow a worrying PSA result, the support systems most men never build, and why getting support should not wait for a crisis.

Tune in to the full episode at https://hubs.la/Q04wpmgK0, and share it with someone who could use it.

09/01/2026

Prostate Cancer Awareness Month is here, and so is our 4th annual PSA on PSA campaign.

This September, we’re teaming up with again to help more men and families start conversations about prostate cancer risk and screening. Download the free factsheet at https://hubs.la/Q04vByt90 and you’ll find information about risk and screening, plus helpful questions to bring to your next doctor’s appointment.

For every factsheet downloaded, Cleveland Diagnostics will make a donation to ZERO, matched throughout the month.

We’re also launching On Call for Men’s Health: A PSA on PSA, a new video series hosted by urologist Dr. Michael Lutz, featuring candid conversations about screening, mental health, access to care, and more. A new episode will be released each week.

Visit https://hubs.la/Q04vByt90 to learn more, and share it with someone who needs it.

08/25/2026

A 62-year-old man presented with elevated PSA (8.1 ng/mL) and a PI-RADS 3 lesion on mpMRI. His IsoPSA Test result was 4.2, within the normal range.

For his urologist, Dr. Arpeet Shah with the Associated Urological Specialists, that additional information provided confidence to avoid biopsy and continue monitoring.

Real-world cases like this highlight how the IsoPSA Test can help provide clinically meaningful information alongside mpMRI.

View more case studies: https://hubs.la/Q04tNlYh0

08/20/2026

PSA remains a valuable screening tool, but it has limitations.

In a recent dialogue with The Pathologist, Dr. Soroush Rais-Bahrami, Professor and Chair of the Department of Urology at Wake Forest University School of Medicine, explores an important question in prostate cancer detection: how can we get more clinically meaningful information from PSA and ancillary tests?

“A concentration-based test tells you that PSA is elevated relative to age-adjusted reference levels, but a structure-based approach may help explain why. That distinction is important when assessing whether an elevated PSA is more likely to reflect prostate cancer or a benign condition,” says Dr. Rais-Bahrami.

https://hubs.la/Q04tDPPj0

08/11/2026

mpMRI has proven to be a valuable tool in the diagnostic pathway for prostate cancer, but it is not without limitations.

The IsoPSA Test can help clarify PI-RADS scores and provide insight when MRI isn’t an option.

Discover how this test can improve biopsy decisions with or without mpMRI: https://hubs.la/Q04skCF00

08/06/2026

What does the future of prostate cancer care look like?

According to Dr. Jason Hafron, it starts with answering two critical questions:
· Who needs treatment?
· What's the best treatment for that patient?

In this short video, he shares why ancillary tests and other advanced tools have the potential to personalize care and support better treatment decisions.

As new evidence emerges, guidelines and best practices for prostate cancer early detection continue to evolve.In this in...
08/05/2026

As new evidence emerges, guidelines and best practices for prostate cancer early detection continue to evolve.

In this interview from AUA 2026, Dr. Badrinath Konety discusses key updates to the 2026 AUA/SUO Early Detection Guidelines, including the roles of MRI, ancillary tests like the IsoPSA Test, and shared decision-making in helping clinicians make more informed biopsy decisions.

Watch the interview and read the full article: https://hubs.ly/Q04qqZ4V0

07/29/2026

Dr. Jason Hafron, Chief Medical Officer at the Michigan Institute of Urology, shares how the IsoPSA Test is helping to bring greater clarity to prostate cancer risk assessment.

While mpMRI is an important tool, it is not always easy to access, and indeterminate findings can leave clinicians and patients with difficult decisions. Dr. Hafron explains how combining the IsoPSA Test with mpMRI helps quantify a patient's risk of clinically significant prostate cancer, supporting more informed decision-making.

Watch the full interview to hear how he incorporates IsoPSA into clinical practice. ⬇️

07/23/2026

For one patient with elevated PSA and a pacemaker, MRI was not appropriate. Dr. Arpeet Shah of Associated Urological Specialists turned to the IsoPSA Test to assess the patient’s risk.

The test revealed an elevated risk result, prompting a biopsy that confirmed Gleason 7 (3+4) prostate cancer.

This case demonstrates how the IsoPSA Test can support confident biopsy decisions even when MRI isn’t available.

Watch the case study for details. ⬇️

If your MRI results do not give clear answers, or if you do not have access to an MRI, the IsoPSA Test can help your doc...
07/21/2026

If your MRI results do not give clear answers, or if you do not have access to an MRI, the IsoPSA Test can help your doctor better understand your risk of prostate cancer. The test can provide additional information and help decide whether a biopsy is the right next step.

See how the IsoPSA Test gives you and your doctor more information to make the right biopsy decision: https://hubs.la/Q04ls7ql0

Address

Cleveland, OH

Telephone

+12164322700

Website

Alerts

Be the first to know and let us send you an email when Cleveland Diagnostics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Cleveland Diagnostics:

Shortcuts

Share

Category